AC
CYT

Aldebaran Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Aldebaran Capital’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-143,739
Closed -$437K – 36
2023
Q4 		$437K Hold
143,739
– – 0.45% 25
2023
Q3 		$408K Hold
143,739
– – 0.42% 25
2023
Q2 		$374K Sell
143,739
-7,500
-5% -$15.7K 0.38% 25
2023
Q1 		$275K Buy
+151,239
New +$246K 0.28% 29

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Aldebaran Capital's CYT Position: Q1 2024 in Review

Aldebaran Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 143,739 shares — an estimated $437K sold.

Aldebaran Capital first reported a position in CYT in Q1 2023 and held it in 4 quarters. The position peaked at $437K in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Aldebaran Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Aldebaran Capital sold 143,739 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $437K.
  • Aldebaran Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Aldebaran Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $437K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Aldebaran Capital's 13F filing for Q1 2024, filed 14 May 2024.